BSH 2017 | Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how minimal residual disease (MRD) detection can be used in the clinic for multiple myeloma (MM) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains how MRD can be used to adjust therapy dosage and determine the response to different treatment. Prof. Landgren also discusses different methods of MRD detection, including new ways to detect MRD in the blood. According to Prof. Landgren, MRD may be more important in determining outcome than the type of therapy given to obtain MRD negativity, and could be used to individualize therapy.
Get great new content delivered to your inboxSign up